PharmaShots | Incisive News in 3 Shots

Subscribe Now

Late-line Treatment

GSK's Zejula (niraparib) Receives FDA's Approval for Late-line Treatment in Women with Recurrent Ovarian Cancer

GSK's Zejula (niraparib) Receives FDA's Approval for Late-line Treatment in Women with Recurrent Ovarian Cancer

October 24, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us